Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Y-mAbs Therapeutics Inc is a biotechnology business based in the US. Y-mAbs Therapeutics shares (YMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Y-mAbs Therapeutics employs 125 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$26.55|
|52-week range||$24.78 - $55.22|
|50-day moving average||$29.45|
|200-day moving average||$31.31|
|Wall St. target price||$55.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.02|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-0.49%|
|1 month (2021-09-24)||-7.49%|
|3 months (2021-07-23)||-24.85%|
|6 months (2021-04-23)||-2.93%|
|1 year (2020-10-23)||-35.84%|
|2 years (2019-10-24)||-11.14%|
|3 years (2018-10-24)||18.58%|
|5 years (2016-10-20)||N/A|
|Revenue TTM||$37.1 million|
|Gross profit TTM||$18.5 million|
|Return on assets TTM||-30.37%|
|Return on equity TTM||-22.24%|
|Market capitalisation||$1.2 billion|
TTM: trailing 12 months
There are currently 2.4 million Y-mAbs Therapeutics shares held short by investors – that's known as Y-mAbs Therapeutics's "short interest". This figure is 10.3% down from 2.7 million last month.
There are a few different ways that this level of interest in shorting Y-mAbs Therapeutics shares can be evaluated.
Y-mAbs Therapeutics's "short interest ratio" (SIR) is the quantity of Y-mAbs Therapeutics shares currently shorted divided by the average quantity of Y-mAbs Therapeutics shares traded daily (recently around 166289.46648427). Y-mAbs Therapeutics's SIR currently stands at 14.62. In other words for every 100,000 Y-mAbs Therapeutics shares traded daily on the market, roughly 14620 shares are currently held short.
However Y-mAbs Therapeutics's short interest can also be evaluated against the total number of Y-mAbs Therapeutics shares, or, against the total number of tradable Y-mAbs Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Y-mAbs Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Y-mAbs Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0702% of the tradable shares (for every 100,000 tradable Y-mAbs Therapeutics shares, roughly 70 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Y-mAbs Therapeutics.
Find out more about how you can short Y-mAbs Therapeutics stock.
We're not expecting Y-mAbs Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Y-mAbs Therapeutics's shares have ranged in value from as little as $24.78 up to $55.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Y-mAbs Therapeutics's is 1.1825. This would suggest that Y-mAbs Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Y-mAbs Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.